Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes

Table 2 Clinical efficacy of treatment for pulmonary Mycobacterium avium complex patients

Subject	Evaluation	Follow-up period (Days)											MIC/(CAM) (μg/mL)	Post follow-up period
Subject	Evaluation	1	29	57	85	113	141	169	225	281	337	365	MIC/(CAM) (μg/mL)	Remarks
B	Sputum culture	1+	– ^a	–	–	–	–	–	–	–	–	–	No data	Relapsed at day 553
B	Chest image		Unchanged	Unchanged	Unchanged	Improved	Unchanged	Unchanged	Unchanged	Unchanged	Unchanged	Improved	No data	Relapsed at day 553
C	Sputum culture	1+	1+	– ^a	–	–	–	No data	1+ ^b	–	1+	1+	0.06
C	Chest image		Unchanged	Unchanged	Improved	Unchanged	Unchanged	Unchanged	Unchanged	Unchanged	Unchanged	Unchanged	(Day 365)
D	Sputum culture	1+	1+	1+	–	1+	1+	1+	1+	1+	1+	1+	0.25
D	Chest image		Unchanged	Unchanged	Improved	Unchanged	Unchanged	Unchanged	Unchanged	Unchanged	Unchanged	Unchanged	(Day 365)
E	Sputum culture	–	1+	–	1+	–	1+	1+	– ^a	–	–	–	0.06	Relapsed at day 589
E	Chest image		Improved	Unchanged	Improved	Unchanged	Worsened	Improved	Unchanged	Unchanged	Unchanged	Unchanged	(Day 169)	Relapsed at day 589

MIC; Minimal inhibitory concentrations, CAM; Clarithromycin
^aCulture negative conversion: the first day of three consecutive negative cultures
^bRelapse: the first day of a positive culture after negative culture conversion

ISSN: 2055-0294